Press inquiries:

Renée Hockaday
240-485-0774
ReneeH@PHAssociation.org

Join our Press List!

Press Releases

July 23, 2014

Stephen L. White Takes Helm as Chair of Pulmonary Hypertension Association Board of Trustees
Dr. Stephen L. White of Hancock, Mass., recently took the helm as Chair of the Board of Trustees for the Pulmonary Hypertension Association.

July 16, 2014

Tom Lantos Innovation in Community Service Awards Given by Pulmonary Hypertension Association to Advance Awareness of Rare Lung Disease
The Pulmonary Hypertension Association (PHA) has awarded 13 committed community activists funding for projects to raise awareness of pulmonary hypertension (PH) - a rare, debilitating disease of the lungs that affects the functioning of the heart and can lead to right heart failure. Without treatment, mean survivability is only 2.8 years.

July 8, 2014

Washington University School of Medicine’s Dr. Murali Chakinala Receives Outstanding Physician Award from Pulmonary Hypertension Association
The Pulmonary Hypertension Association (PHA), the nation’s leading pulmonary hypertension organization, presented Murali Chakinala, MD, FCCP, with its Outstanding Physician Award during PHA’s 11th Biennial Conference and Scientific Sessions June 20-22, 2014. Conference helps to foster networking and bring hope to patients, caregivers and medical professionals working to live with and find a cure for pulmonary hypertension – a disease of the lungs that affects the functioning of the heart and can lead to right heart failure. Without treatment, mean survivability is only 2.8 years.

June 16, 2014

Pulmonary Hypertension Association to Hold International Conference and Scientific Sessions in Indianapolis as Patients, Caregivers and Medical Professionals Race for a Cure
Pulmonary Hypertension Association (PHA), the nation's leading pulmonary hypertension organization, is meeting in Indianapolis, Ind., June 20-22 to educate, foster networking and bring hope to patients, caregivers and medical professionals working to live with and find a cure for pulmonary hypertension.

June 4, 2014

Pulmonary Hypertension Association Supports Team Phenomenal Hope as it Prepares to Race Across America and Bring Awareness to Rare Lung Disease
Beginning on June 14, 2014, Team Phenomenal Hope, a Pittsburgh, Pa.-based cycling team consisting of a lung transplant physician and three other women, is competing in the high-endurance cycling event, Race Across America (RAAM), to raise awareness of pulmonary hypertension (PH). The race kicks off from Oceanside, Calif., and will end in Annapolis, Md.

Feb. 24, 2014

Discovery of Genetic Mutations That Cause Deadly Lung Disease Applauded by Patient Organization
A team of researchers, led by physicians and scientists at Intermountain Healthcare's Intermountain Medical Center and ARUP Laboratories, has made a medical breakthrough by discovering genetic mutations that cause a rare and deadly lung disease. Read full press release

Dec. 22, 2013

New Pulmonary Hypertension Drug Approved!

The U.S. Food and Drug Administration (FDA) approved United Therapeutics' oral treprostinil, an extended-release tablet commercially known as Orenitram, for the treatment of pulmonary arterial hypertension (PAH). Orenitram is the first orally administered prostacyclin analogue approved by the FDA for any disease.

Oct. 10, 2013

FDA Approves Tenth Drug for One Rare Disease Affecting Just 20-30,000 Patients: Pulmonary Hypertension Association Highlights Factors Contributing to Rapid Progress
The US Food and Drug Administration this week approved the tenth treatment, riociguat, for pulmonary hypertension (PH), a rare and life-threatening lung disease affecting roughly 20,000-30,000 patients, continuing the remarkable pace of recent progress that distinguishes PH from all but a handful of the 7,000 other rare diseases in this country. An eleventh PH drug will be considered by the FDA later this month. Read full press release

Oct. 3, 2013

Consensus Guidelines Published on Screening for PAH in Systemic Sclerosis; Recommendations Aim For Earlier Diagnosis of This Leading Cause of Mortality

All patients with systemic sclerosis (SSc) and connective tissue diseases should be screened for pulmonary arterial hypertension (PAH), an international panel of experts recommended in an article published in the September issue of the journal Arthritis & Rheumatism.  The recommendations, part of a larger effort to improve patient outcomes by diagnosing earlier, identify specific tests to be performed in screening these patients for PAH.  Read full press release

May 8, 2013

30 Years of Orphan Drug Act, Combined with Science and Advocacy, Reflect Dramatic Progress in a Rare Lung Disease

Pulmonary hypertension (PH), a rare and life-threatening lung disease, has gone from rapidly fatal to treatable with nine drugs developed in just the past 20 years, a phenomenal record for a rare condition. Growth in the understanding and treatment of PH reflects the dramatic progress possible since the passage of the Orphan Drug Act 30 years ago, according to the Pulmonary Hypertension Association (PHA), www.PHAssociation.org. Read full press release

Resources For Reporting on the Impact of the 1983 Orphan Drug Act (PDF)

6/21/12

Early Diagnosis Campaign Launched for Pulmonary Hypertension

Despite rapid progress in treatment for pulmonary hypertension (PH), an incurable lung disease, repeated misdiagnosis causes many patients to receive care only at advanced stages of the illness. In response, the Pulmonary Hypertension Association today launched an early diagnosis campaign to educate healthcare professionals to spot this disease and to refer patients earlier to specialty PH care.

5/17/11

Pulmonary Hypertension Association Names Dr. Ronald Oudiz Recipient of 2011 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care

The Pulmonary Hypertension Association (PHA), the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and Actelion Pharmaceuticals US, Inc., today announced that Dr. Ronald Oudiz of LA BioMed is the 2011 recipient of the Pulmonary Hypertension Association (PHA) Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care. This annual award is designed to honor and acknowledge healthcare professionals who are committed to improving outcomes for patients with PAH through excellence in research and clinical practice.

11/24/11

Rare but Equal, Pulmonary Hypertension and Other Unknown Diseases Impact Lives Worldwide

Pulmonary hypertension (PH) is a rare, under-diagnosed disease that can strike people at any time, affecting newborns to the elderly or anyone in between. To raise global awareness of this invisible disease, the Pulmonary Hypertension Association (PHA) is partnering with the National Organization for Rare Disorders (NORD) and Rare Diseases Europe (EURORDIS) on Feb. 28, 2011, to observe Rare Disease Day.

12/14/10

Taking Your Own Air, Up In the Air

This holiday season, nearly 50 million people will take to the air. Some will have to bring their own portable air in order to make it safely to their destination. The Pulmonary Hypertension Association, the national center for advocacy, education and events related to pulmonary hypertension (PH), offers travel tips for people relying on portable oxygen - including those living with PH.

10/21/10

Misdiagnosis All Too Common for People Living with Pulmonary Hypertension

Twenty-five years ago pulmonary hypertension (PH) patients had a 50-percent chance of surviving 2.8 years past diagnosis, but with new treatment options and the care of a PH specialist, more patients are living longer. This November, during Pulmonary Hypertension Awareness Month, they are working to ensure that the prognosis for this invisible, incurable disease continues to improve.

3/29/10

Kentucky Mother Galvanizes Community to Pucker Up in Memory of Her Daughter

Orena Alsip of London, Kentucky will introduce the 2010 PuckerUp4PH Campaign in the U.S., March 29 – April 3 at South Laurel County High School in memory of her 14-year-old daughter Amber Newby who passed away from pulmonary hypertension (PH) in January.

2/19/10

Healthcare Professionals Climb Mt. Kilimanjaro to Raise Awareness of Serious Lung Disease

The Pulmonary Hypertension Association announced today that three pulmonary hypertension specialists began their eight-day “Path to a Cure” journey to the 19,341-foot summit of Mt. Kilimanjaro to raise global awareness of PH, a disease that affects the heart and lungs. Spanish (Doc) | Danish (Doc)

12/18/09

PHA Offers Air Travel Tips for Patients Using Portable Oxygen

This holiday season, the Pulmonary Hypertension Association, the national center for advocacy, education, and events related to pulmonary hypertension, offers tips for patients relying on portable oxygen - including people living with pulmonary hypertension.

6/16/09

New Source of Information on Pulmonary Hypertension Medications

PHA recently collaborated with NeedyMeds, a non-profit that connects patients who cannot afford their treatment to various prescription assistance programs and resources, to create a PH-specific resource page.

5/18/2009

Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care

The Pulmonary Hypertension Association (PHA), Tufts Medical Center, and Actelion Pharmaceuticals US, Inc., today announced Dr. Nicholas Hill of Tufts Medical Center as the recipient of the 2009 PHA Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care.

3/13/2009

For Pulmonary Hypertension Community, Research and Education Act a Labor of Love

Pulmonary hypertension (PH) patients don’t have a lot of breath to spare, but the PH community is doing what it takes to spread the word about the Tom Lantos Pulmonary Hypertension Research and Education Act of 2009 (H.R. 1030). The bill was introduced February 13 by Representative Kevin Brady (R-TX) and Representative Lois Capps (D-CA) who, despite their parties’ differences, are united in their fight against this rare, incurable disease.

12/2/2008

Pucker Up 4 PH Campaign collects kisses to raise awareness of pulmonary hypertension

The Pucker Up 4 PH Campaign, organized by the PHA in the United Kingdom (PHA-UK), is part of an international effort among the 47 PH associations in countries around the world to raise awareness of PH by collecting blue kisses.

Browse the PHA Press Release Archive

 

Feb. 24, 2014

New Pulmonary Hypertension Drug Approved!

The U.S. Food and Drug Administration (FDA) approved United Therapeutics' oral treprostinil, an extended-release tablet commercially known as Orenitram, for the treatment of pulmonary arterial hypertension (PAH). Orenitram is the first orally administered prostacyclin analogue approved by the FDA for any disease.

 

Feb. 24, 2014

New Pulmonary Hypertension Drug Approved!

The U.S. Food and Drug Administration (FDA) approved United Therapeutics' oral treprostinil, an extended-release tablet commercially known as Orenitram, for the treatment of pulmonary arterial hypertension (PAH). Orenitram is the first orally administered prostacyclin analogue approved by the FDA for any disease.

 

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

For the best viewing experience of this site, it is recommended that you use Internet Explorer 8 or 9 or Firefox.

© 2014 Pulmonary Hypertension Association. All Rights Reserved.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.®

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.